mass confirmation is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
== Vaccination Campaign == On 13 November, the government of Sudan requested help from the International Coordinating Group on Yellow Fever Vaccine Provision (YF-ICG) in starting a mass vaccination campaign. Besides the WHO, the YF-ICG consists of representatives of the United Nations Children's Fund (UNICEF), Médecins sans Frontières (MSF) and the International Federation of Red Cross and Red Crescent Societies (IFRC). The United Nations–African Union Mission in Darfur (UNAMID) airlifted the first batches of vaccines from Khartoum to Darfur on 18 November. Mass vaccination began on 20 November. Efforts were also undertaken to eliminate mosquitoes. A team from the Naval Medical Research Unit Three (NAMRU-3) and the WHO Collaborating Center was deployed from Cairo to help collect and test samples and train local personnel. The vaccination campaign, from late November 2012 through early January 2013, covered more than 3 million people and halted the outbreak. A new phase of the campaign beginning in January covered more than 2 million more people at risk. One of the difficulties was maintaining a cold chain for vaccine viability while transporting vaccine by donkey into remote areas. A situation report released on 10 January 2013 reported that 171 people had died of the disease as of 9 January 2013. The number of suspected cases since 2 September 2012 was 847. The Minister of Health had announced on 5 January that no additional cases had appeared in the previous 3 weeks.
Hops are the female flower clusters or seed cones of the hop vine Humulus lupulus, which are used as a flavouring and preservative agent in nearly all beer made today. Hops had been used for medicinal and food flavouring purposes since Roman times; by the 7th century in Carolingian monasteries in what is now Germany, beer was being made with hops, though it isn't until the thirteenth century that widespread cultivation of hops for use in beer is recorded. Before the thirteenth century, beer was flavoured with plants such as yarrow, wild rosemary, and bog myrtle, and other ingredients such as juniper berries, aniseed and ginger, which would be combined into a mixture known as gruit and used as hops are now used; between the thirteenth and the sixteenth century, during which hops took over as the dominant flavouring, beer flavoured with gruit was known as ale, while beer flavoured with hops was known as beer. Some beers today, such as Fraoch by the Scottish Williams Bros Brewing Company and Cervoise Lancelot by the French Brasserie Lancelot, use plants other than hops for flavouring. Hops contain several characteristics that brewers desire in beer: they contribute a bitterness that balances the sweetness of the malt; they provide floral, citrus, and herbal aromas and flavours; they have an antibiotic effect that favours the activity of brewer's yeast over less desirable microorganisms; and they aid in "head retention", the length of time that the foam on top of the beer (the beer head) will last.
=== Phase out of single-use plastic straws === On July 9, 2018, Starbucks President and CEO Kevin Johnson announced that Starbucks would phase out the single-use plastic straws by January 1, 2020, on all cold drinks from all locations worldwide due to climate change concerns, pollution, and sea turtle endangerment as the single-use plastic straws failed to be designed for recycling when they were invented. Frappucinos would get straws made from a different material that is sustainable and environmentally friendly such as paper or compostable plastic, while other cold drinks would get straw-less lids. These new modified lids contain 9% less plastic than Starbucks' previous flat lid. The Starbucks locations in Europe, China, Taiwan, Japan, Thailand, Vietnam, India, Canada, Hawaii, Alaska, Washington D.C., New Mexico, California, New York, Washington State, New Jersey, Oregon, Maryland, Delaware, Vermont, Massachusetts, Connecticut, and Rhode Island already eliminated single-use plastic straws by the end of 2018. South Korea is the first country to introduce paper straws to all stores among 78 countries in the world that Starbucks has entered.
Sources: en.wikipedia.org
The two substrates of this enzyme are galactitol-1-phosphate and oxidised nicotinamide adenine dinucleotide (NAD+). Its 3 products are L-tagatose 6-phosphate (shown in its open-chain keto form), reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is galactitol-1-phosphate:NAD+ oxidoreductase. This enzyme participates in galactose metabolism. It employs one cofactor, zinc.
showed that small molecule inhibitors of Prp8 intein splicing were selective and effective at slowing the growth of C. neoformans and C. gattii, providing exciting evidence for the antimicrobial potential of intein splicing inhibitors.
Certain aspects of the instrumentation (such as detection) are necessarily more complex than for a single-capillary system, but the fundamental principles of design and operation are similar to those shown in Figure 1.
The Academy of Television Arts & Sciences acknowledged season 3 at their Primetime Emmy Award ceremonies seven times. At the 78th Primetime Emmy Awards, the season got one nomination; Zendaya's turn in episode eight "In God We Trust" was nominated for her third Outstanding Lead Actress in a Drama Series. At the 78th Primetime Creative Arts Emmy Awards, the season was nominated for Outstanding Guest Actor in a Drama Series (Domingo for the series finale), Outstanding Cinematography for a Series (One Hour) (Marcell Rév for the series finale), Outstanding Picture Editing for a Drama Series (Nikola Boyanov, Aleshka Ferrero, Aaron I. Butler, Julio C. Perez IV, and Kristin Valentine for "In God We Trust"), Outstanding Production Design for a Narrative Contemporary Program (One Hour or More) (François Audouy, A. Todd Holland, and Anthony Carlino for episode five "This Little Piggy"), Outstanding Hairstyling (Kimberly Kimble, Kendra Garvey, Kase Glenn, Marquita Lynch, and Stacy Schneiderman for episode three "The Ballad of Paladin"), and Outstanding Makeup (Non-Prosthetic) (Doniella Davy, Mara Rouse, Tara Lang Shah, and Leah Rial Sappington for episode four "Kitty Likes to Dance").
Sources: en.wikipedia.org
S: The number of susceptible individuals. When a susceptible and an infectious individual come into "infectious contact", the susceptible individual contracts the disease and transitions to the infectious compartment. I: The number of infectious individuals. These are individuals who have been infected and are capable of infecting susceptible individuals. R for the number of removed (and immune) or deceased individuals. These are individuals who have been infected and have either recovered from the disease and entered the removed compartment, or died. It is assumed that the number of deaths is negligible with respect to the total population. This compartment may also be called "recovered" or "resistant". This model is reasonably predictive for infectious diseases that are transmitted from human to human, and where recovery confers lasting resistance, such as measles, mumps, and rubella.
9 May – Protesters gather in several centres including Auckland, Dunedin, Christchurch, Rolleston and New Plymouth to protest against the Government's new Pay Equality Amendment Act 2025. 10 May – Protest against the Government's new Pay Equity legislation are held in Nelson and Ōtaki. 11 May – The Christchurch City Council extends the state of emergency in Banks Peninsula in response to a landslip in Akaroa. 12 May: Mayor of Christchurch Phil Mauger lifts Banks Peninsula's local state of emergency. Deputy Police Commissioner Jevon McSkimming resigns following a four-month Police and Independent Police Conduct Authority investigation into serious misconduct including pornography being found on a Police-issued device. 14 May – A parliamentary committee approves a motion against Te Pāti Māori MPs Hana-Rāwhiti Maipi-Clarke, Rawiri Waititi and Debbie Ngarewa-Packer censuring and banning them from entering the parliamentary buildings for up to 21 days for their performance of a haka against their opponents during a parliamentary debate over the Treaty Principles Bill. 15 May – The New Zealand Government apologises to the Māori iwi Ngāti Ranginui for land confiscations and a scorched earth campaign during the New Zealand Wars. Parliament also passes legislation compensating the tribe NZ$38 million and designating 15 sites of significances to the tribe. 16 May: The USS Blue Ridge visited Wellington to reaffirm bilateral relations with New Zealand. This marked the first visit to Wellington by a US warship since 2021.
Hydrophobic interaction chromatography (HIC) can also be used for first and/ or intermediate steps. Selectivity in HIC is independent of running pH and descending salt gradients are used. For HIC, conditioning involves adding ammonium sulfate to the sample to match the buffer A concentration. If HIC is used before IEC, the ionic strength would have to be lowered to match that of buffer A for IEC step by dilution, dialysis or buffer exchange by gel filtration. This is why IEC is usually performed prior to HIC as the high salt elution conditions for IEC are ideal for binding to HIC resins in the next purification step. Polishing is used to achieve the final level of purification required and is commonly performed on a gel filtration column. An extra intermediate purification step can be added or optimization of the different steps is performed for improving purity. This extra step usually involves another round of IEC under completely different conditions. Although this is an example of a common purification protocol for proteins, the buffer conditions, flow rates, and resins used to achieve final goals can be chosen to cover a broad range of target proteins. This flexibility is imperative for a functional purification system as all proteins behave differently and often deviate from predictions.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
The lyophilised powder is typically held at -20 C or lower in a dry, dark place. Reconstituted solutions are aliquoted and frozen to avoid repeated freeze-thaw cycles.